Healthcare Review: OXiGENE, Biosante Pharmaceuticals, Targacept, AEterna Zentaris Are Top Gainers Print E-mail
By Staff and Wire Reports   
Tuesday, 18 September 2012 14:52
U.S. stocks fell slightly on Tuesday as investors looked to economic data this week for direction after a rally that was driven primarily by central banks' stimulus policies. U.S. homebuilder sentiment rose for the fifth month in a row in September to its highest level in over six years in a fresh sign of momentum for the housing market, a report from the National Association of Home Builders showed. Several healthcare stocks are making notable news at mid day on Tuesday.

OXiGENE, Inc.(NASDAQ:OXGN)
shares jumped 24.99% to $0.686 after the company announced yesterday that it has come to agreement with the U.S. Food and Drug Administration or FDA on a Special Protocol Assessment or SPA for its Phase 3 clinical trial or FACT 2 of Zybrestat for the treatment of anaplastic thyroid cancer or ATC.

The company noted that the FACT 2 study is designed as a randomized, placebo-controlled, double-blinded study of 300 subjects randomized 1:1 to receive carboplatin and paclitaxel plus fosbretabulin versus carboplatin and paclitaxel plus placebo.

Biosante Pharmaceuticals Inc (NASDAQ:BPAX)
shares climbed 12.89% to $2.12. The company announced that the independent Data Monitoring Committee or DMC has completed the ninth unblinded review of the LibiGel Phase III cardiovascular events and breast cancer safety study. The independent DMC has recommended that the LibiGel safety study should continue as per the FDA-agreed protocol, without modifications. LibiGel is in development for the treatment of female sexual dysfunction or FSD, specifically, hypoactive sexual desire disorder or HSDD in menopausal women.

Targacept , Inc.(NASDAQ:TRGT)
shares gained 8.61% to $4.68. The company yesterday said that it will no longer develop TC-5619 as a treatment for adults with inattentive-predominant attention deficit/hyperactivity disorder, because the drug didn't meet the primary endpoints of a Phase II study. Additionally, the company said it will cut more jobs and limit investments to its ongoing or previously announced clinical programs until it finds a new chief executive. Further details weren't disclosed.

AEterna Zentaris Inc. (USA) (NASDAQ:AEZS)
shares increased 11.43% to $0.700 in the morning hour. The company, on Sept. 7, said that it has recruited the first patient for a Phase IIA trial with its ghrelin agonist, AEZS-130 in patients with cancer cachexia. The study is conducted under a Cooperative R&D Agreement, or CRADA, between Aeterna Zentaris and the Michael DeBakey Veterans Affairs Medical Center which is funding the study.

Sequenom, Inc.(NASDAQ:SQNM)
stock fell 0.25% to $3.98 after the company yesterday announced the completion of its offering of $130.0 million aggregate principal amount of 5.00% Convertible Senior Notes due 2017 in a private offering, including $20.0 million aggregate principal amount of notes sold pursuant to the full exercise of an over-allotment option previously granted to the initial purchasers.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter